- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03226821
Body Composition and Adipose Tissue in HIV
October 24, 2022 updated by: Pamela U. Freda, Columbia University
Body Composition and Adipose Tissue in HIV Lipodystrophy: Effects of Tesamorelin Therapy
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity.
This study is a single arm prospective study of tesamorelin therapy of patients with HIV lipodystrophy.
Subjects will do body composition testing, adipose tissue biopsy, metabolic rate measurements and insulin sensitivity assessment before, 6 and 12 months after daily injections of tesamorelin 2 mg by subcutaneous injection.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
HIV lipodystrophy is increasingly recognized as a common and clinically significant long-term sequelae of HIV treatment.
In the HIV lipodystrophy lipohypertrophy phenotype, visceral adipose tissue (VAT) is increased and this is associated with reduced growth hormone (GH) secretion.
Mounting evidence also links this phenotype with dyslipidemia, insulin resistance, subclinical atherosclerosis and cardiovascular (CV) disease in patients with HIV disease.
The etiology of HIV lipodystrophy (HIVLD) with central adiposity is unclear, but this phenotype is increasingly common with newer, less lipotoxic combination anti-retroviral therapy (cART) use.
VAT and hepatic lipid accumulation, are important health concerns for HIVLD patients.
This body composition pattern may contribute to the increased cardiovascular risk that has been demonstrated in patients with HIV lipodystrophy.
Patients with HIVLD and central adiposity have been shown to have reduced GH secretion.
Thus, a medication has been developed to augment GH secretion.
This medication is tesamorelin.
GH supplementation in other clinical settings has been shown to reduce visceral adiposity and may reduce hepatic lipid content.
Study Type
Interventional
Enrollment (Anticipated)
24
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Carlos Reyes-Vidal, MD
- Phone Number: 212-305-4921
- Email: csr52@columbia.edu
Study Contact Backup
- Name: Pamela Freda, MD
- Phone Number: 212-305-2254
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Neuroendocrine Unit and Pituitary Center, Columbia University
-
Contact:
- Pamela U. Freda, MD
- Phone Number: 212-305-2254
-
Contact:
- Carlos M. Reyes-Vidal, MD
- Phone Number: 212-305-4921
- Email: csr52@cumc.columbia.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 66 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- HIV-infected subjects with HIV lipodystrophy (HIVLD)
- Abdominal fat accumulation defined as: Waist Circumference (WC) 102 cm for men, 88 cm for women, except in subjects of East/South Asian ethnicity in whom this will be defined by WC 90 cm for men and 80 cm for women.
- Weight stable for 8 weeks prior to enrollment,
- CD4 count >100 cells/mm3
- HIV RNA load <1000 copies/mL
- Fasting plasma glucose <120 mg/dL
- Stable combination anti-retroviral therapy (cART) of any regimen for ≥ 8 weeks prior to study enrollment
Exclusion Criteria:
- Diabetes mellitus requiring medication
- History of any malignancy
- Abnormal renal or liver function
- Pregnancy or women of childbearing age who are not using an acceptable means of contraception
- History disorder of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism or pituitary tumor/surgery
- Head irradiation or head trauma or adrenal insufficiency
- Systemic glucocorticoid use
- Known hypersensitivity to tesamorelin and/or mannitol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tesamorelin
Subjects will be treated with tesamorelin 2 mg by subcutaneous injection daily.
Enrolled subjects will have 6 visits - a baseline visit before starting tesamorelin, a visit at 1 month, 3 months, 6 months, 9 months and at 1 year of tesamorelin (GHRH analogue) therapy.
Blood sampling for safety labs and clinical examinations will be performed at each visit.
|
Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Hepatic Lipid Content
Time Frame: Baseline and 12 months
|
Hepatic lipid content measured by abdominal magnetic resonance imaging (MRI)
|
Baseline and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Visceral Adipose Tissue (VAT) mass
Time Frame: Baseline and 12 months
|
Visceral adipose tissue mass measured by abdominal MRI
|
Baseline and 12 months
|
Change in Relative gene expression of CD68 gene
Time Frame: Baseline and 12 months
|
Relative gene expression of CD68 gene in adipose tissue
|
Baseline and 12 months
|
Change in Relative gene expression on TNF-alpha gene
Time Frame: Baseline and 12 months
|
Relative gene expression of tumor necrosis factor (TNF)-alpha gene in adipose tissue
|
Baseline and 12 months
|
Change in Resting Energy Expenditure (REE)
Time Frame: Baseline and 12 months
|
Resting metabolic rate measured by indirect calorimetry
|
Baseline and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Pamela U. Freda, MD, Columbia University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 7, 2018
Primary Completion (Anticipated)
April 30, 2023
Study Completion (Anticipated)
April 30, 2023
Study Registration Dates
First Submitted
July 20, 2017
First Submitted That Met QC Criteria
July 20, 2017
First Posted (Actual)
July 24, 2017
Study Record Updates
Last Update Posted (Actual)
October 26, 2022
Last Update Submitted That Met QC Criteria
October 24, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Skin Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Lipid Metabolism Disorders
- HIV Infections
- Skin Diseases, Metabolic
- Lipodystrophy
- HIV-Associated Lipodystrophy Syndrome
- Physiological Effects of Drugs
- Growth Substances
- Tesamorelin
Other Study ID Numbers
- AAAR2634
- R01DK110771 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Body Composition
-
Nova Southeastern UniversityCompleted
-
Centro Universitario de Ciencias de la Salud, MexicoCompleted
-
University of Southern CaliforniaCompleted
-
University of California, San FranciscoHologic, Inc.Completed
-
University of SurreyUnknownBody Composition
-
Texas Woman's UniversityCompleted
-
Auburn UniversityCompletedBody CompositionUnited States
-
Universidad de ZaragozaUnknown
-
University Hospital, Clermont-FerrandCenter of study in Human Nutrition, INRA, Department of Clinical NutritionCompleted
-
Muğla Sıtkı Koçman UniversityBahçeşehir UniversityCompleted
Clinical Trials on Tesamorelin
-
Massachusetts General HospitalNational Institute of Allergy and Infectious Diseases (NIAID)CompletedNonalcoholic Steatohepatitis (NASH) | Human Immunodeficiency Virus (HIV) | Nonalcoholic Fatty Liver Disease (NAFLD)United States
-
TheratechnologiesTerminated
-
Johns Hopkins UniversityWithdrawn
-
Johns Hopkins UniversityUnited States Department of DefenseRecruitingPeripheral Nerve InjuriesUnited States
-
TheratechnologiesCompletedType 2 Diabetes
-
University of California, San DiegoUniversity of Southern California; University of California, San Francisco; PalmTree...Active, not recruitingMild Cognitive ImpairmentUnited States
-
TheratechnologiesCompletedHIV Infections | LipodystrophyCanada, France, United States, United Kingdom, Spain, Belgium
-
National Institute of Nursing Research (NINR)WithdrawnSleep Disorder | Traumatic Brain Injury
-
Massachusetts General HospitalWithdrawnAbdominal ObesityUnited States
-
TheratechnologiesCompleted